Blockchain Registration Transaction Record
Clene Announces Key Updates on NIH-Funded Expanded Access Program for CNM-Au8 Compassionate Use in ALS
Clene (CLNN) announces key updates on NIH-funded Expanded Access Program for CNM-Au8 compassionate use in ALS, highlighting the potential impact of the investigational drug in treating neurodegenerative diseases.
This news matters because it highlights the progress and potential impact of Clene's investigational drug CNM-Au8 in providing a treatment option for the ALS community. The positive results from the Phase 2 clinical studies and the NIH-funded EAP demonstrate the company's commitment to improving mitochondrial health and protecting neuronal function in neurodegenerative diseases.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0x9f80773085a2e0490fb2a3ca7f7a39547b9ae1aab88ac5616f69085aa53f7183 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | chef9e7P-1c8a13374a60492255228b1da326fa0c |